Drug recall · June 26, 2013
Norpace CR recall
Why: Failed Dissolution Specification
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Norpace CR (disopyramide phosphate) extended-release capsules USP,150 mg, packaged in a) 100-count bottles (NDC 0025-2742-31), and b) 500-count bottles (NDC 0025-2742-51), Rx only, Distributed by G.D. Searle LLC, Division of Pfizer Inc, NY, NY 10017.
- Lots / codes
Lot #: a) C120138, Exp 07/13; b) C120137, Exp 07/13
- Quantity
- 5,410 botlles
- Company
- Pfizer Inc, Peapack, NJ
- Distribution
- Nationwide and Puerto Rico
- Initiated
- May 31, 2013 · Voluntary: Firm initiated
- Classified
- June 19, 2013
- Reported
- June 26, 2013
- Ended
- June 5, 2015
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Disopyramide
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.